Topical clindamycin for acne vulgaris: analysis of gastrointestinal events
Conclusions: According to pharmacovigilance data, the rate of GI adverse drug reactions with topical clindamycin-containing products was 0.000045% (64/141,084,533). Results from two retrospective medical record studies of patients with AV indicated that physicians prescribe topical clindamycin equally to patients with or without inflammatory bowel disease history, and that rates of pseudomembranous colitis in these patients were low. In 8 published pivotal clinical trials of topical clindamycin for AV, GI AEs were reported in 1.4% of participants. Limitations include under/inaccurate reporting of AEs or prescription data a...
Source: Journal of Dermatological Treatment - April 3, 2024 Category: Dermatology Authors: Natalia M Pelet Del Toro Andrew Strunk Jashin J Wu Linda Stein Gold James Q Del Rosso Robert T Brodell George Han Source Type: research

A systematic review investigating the proportion of clinical images shared in prospective randomized controlled trials involving patients with atopic dermatitis and systemic pharmacotherapy
J Dermatolog Treat. 2024 Dec;35(1):2338280. doi: 10.1080/09546634.2024.2338280. Epub 2024 Apr 3.ABSTRACTFor individuals with atopic dermatitis (AD), interpreting scientific papers that present clinical outcomes including the Eczema Area and Severity Index (EASI) and Investigators Global Assessment may be difficult. When compared to tabulated data and graphs, images from before and after treatment are often far more meaningful to these patients that ultimately will be candidates for the treatment. This systematic review focused on determining the frequency of clinical image sharing in AD research.Conducted in accordance wit...
Source: Journal of Dermatological Treatment - April 3, 2024 Category: Dermatology Authors: Sam Polesie Mikael Alsterholm Source Type: research

Topical clindamycin for acne vulgaris: analysis of gastrointestinal events
Conclusions: According to pharmacovigilance data, the rate of GI adverse drug reactions with topical clindamycin-containing products was 0.000045% (64/141,084,533). Results from two retrospective medical record studies of patients with AV indicated that physicians prescribe topical clindamycin equally to patients with or without inflammatory bowel disease history, and that rates of pseudomembranous colitis in these patients were low. In 8 published pivotal clinical trials of topical clindamycin for AV, GI AEs were reported in 1.4% of participants. Limitations include under/inaccurate reporting of AEs or prescription data a...
Source: Journal of Dermatological Treatment - April 3, 2024 Category: Dermatology Authors: Natalia M Pelet Del Toro Andrew Strunk Jashin J Wu Linda Stein Gold James Q Del Rosso Robert T Brodell George Han Source Type: research

A systematic review investigating the proportion of clinical images shared in prospective randomized controlled trials involving patients with atopic dermatitis and systemic pharmacotherapy
J Dermatolog Treat. 2024 Dec;35(1):2338280. doi: 10.1080/09546634.2024.2338280. Epub 2024 Apr 3.ABSTRACTFor individuals with atopic dermatitis (AD), interpreting scientific papers that present clinical outcomes including the Eczema Area and Severity Index (EASI) and Investigators Global Assessment may be difficult. When compared to tabulated data and graphs, images from before and after treatment are often far more meaningful to these patients that ultimately will be candidates for the treatment. This systematic review focused on determining the frequency of clinical image sharing in AD research.Conducted in accordance wit...
Source: Journal of Dermatological Treatment - April 3, 2024 Category: Dermatology Authors: Sam Polesie Mikael Alsterholm Source Type: research

Topical clindamycin for acne vulgaris: analysis of gastrointestinal events
Conclusions: According to pharmacovigilance data, the rate of GI adverse drug reactions with topical clindamycin-containing products was 0.000045% (64/141,084,533). Results from two retrospective medical record studies of patients with AV indicated that physicians prescribe topical clindamycin equally to patients with or without inflammatory bowel disease history, and that rates of pseudomembranous colitis in these patients were low. In 8 published pivotal clinical trials of topical clindamycin for AV, GI AEs were reported in 1.4% of participants. Limitations include under/inaccurate reporting of AEs or prescription data a...
Source: Journal of Dermatological Treatment - April 3, 2024 Category: Dermatology Authors: Natalia M Pelet Del Toro Andrew Strunk Jashin J Wu Linda Stein Gold James Q Del Rosso Robert T Brodell George Han Source Type: research

A systematic review investigating the proportion of clinical images shared in prospective randomized controlled trials involving patients with atopic dermatitis and systemic pharmacotherapy
J Dermatolog Treat. 2024 Dec;35(1):2338280. doi: 10.1080/09546634.2024.2338280. Epub 2024 Apr 3.ABSTRACTFor individuals with atopic dermatitis (AD), interpreting scientific papers that present clinical outcomes including the Eczema Area and Severity Index (EASI) and Investigators Global Assessment may be difficult. When compared to tabulated data and graphs, images from before and after treatment are often far more meaningful to these patients that ultimately will be candidates for the treatment. This systematic review focused on determining the frequency of clinical image sharing in AD research.Conducted in accordance wit...
Source: Journal of Dermatological Treatment - April 3, 2024 Category: Dermatology Authors: Sam Polesie Mikael Alsterholm Source Type: research

Managing dry skin in patients with comorbidities or with advanced age: unmet needs and roles for products containing potential emollient-plus ingredients
J Dermatolog Treat. 2024 Dec;35(1):2326171. doi: 10.1080/09546634.2024.2326171. Epub 2024 Apr 2.ABSTRACTIn dry skin (DS), skin-barrier function is easily disturbed and moisturizing factors in the stratum corneum are reduced. Despite being a common condition, DS is often overlooked in patients with advanced age or comorbid diseases. In September 2022, specialists in dermatology and skin care met to discuss unmet needs and management of patients with DS with existing medical conditions or DS induced by ongoing pharmacological treatments. There was consensus about the need to improve the current understanding and management o...
Source: Journal of Dermatological Treatment - April 2, 2024 Category: Dermatology Authors: Matthias Augustin Enzo Berardesca Ulrike Blume-Peytavi Peter Elsner Davide Scafa Leonard Christopher Schmeel Ehrhardt Proksch Source Type: research

Successful treatment of recalcitrant generalized pustular psoriasis of pregnancy with spesolimab
J Dermatolog Treat. 2024 Dec;35(1):2334791. doi: 10.1080/09546634.2024.2334791. Epub 2024 Apr 2.ABSTRACTGeneralized pustular psoriasis (GPP) in pregnancy can lead to severe complications for both mother and fetus. The treatment of this disease is challenging, especially in recalcitrant and severe cases. Until present, there are no evidence-based guidelines for the treatment of GPP in pregnancy. Spesolimab, a human monoclonal antibody against the IL-36 receptor, has recently attracted attention as a new therapy for GPP flare. This biologic provides rapid and sustained control of symptoms of GPP flare, although its use in pr...
Source: Journal of Dermatological Treatment - April 2, 2024 Category: Dermatology Authors: Chenxin Yang Yang Wang Ruoyu Li Ping Tu Ruojun Wang Source Type: research

Use of a topical Janus kinase inhibitor in immune checkpoint inhibitor-induced eczematous reaction: a case report
In this report, we describe the case of a 28-year-old female with bilateral breast cancer in the setting of a BRCA1 mutation, who presented to dermatology with an eczematous reaction, ultimately diagnosed as a cutaneous immune-related adverse event (cirAE) secondary to an immune checkpoint inhibitor (ICI), pembrolizumab. Our case report highlights a novel therapeutic option for an eczematous cirAE: the topical JAK 1/2 inhibitor, ruxolitinib. CirAEs can occur in up to 55% of patients on ICIs, a class of medications seeing rapidly increasing use in cancer therapy, and prior research has demonstrated that ICI-induced dermatit...
Source: Journal of Dermatological Treatment - April 2, 2024 Category: Dermatology Authors: Camille M Powers Hannah Verma Jeremy Orloff Austin J Piontkowski Amy Tiersten Angela Lamb Nicholas Gulati Source Type: research

Managing dry skin in patients with comorbidities or with advanced age: unmet needs and roles for products containing potential emollient-plus ingredients
J Dermatolog Treat. 2024 Dec;35(1):2326171. doi: 10.1080/09546634.2024.2326171. Epub 2024 Apr 2.ABSTRACTIn dry skin (DS), skin-barrier function is easily disturbed and moisturizing factors in the stratum corneum are reduced. Despite being a common condition, DS is often overlooked in patients with advanced age or comorbid diseases. In September 2022, specialists in dermatology and skin care met to discuss unmet needs and management of patients with DS with existing medical conditions or DS induced by ongoing pharmacological treatments. There was consensus about the need to improve the current understanding and management o...
Source: Journal of Dermatological Treatment - April 2, 2024 Category: Dermatology Authors: Matthias Augustin Enzo Berardesca Ulrike Blume-Peytavi Peter Elsner Davide Scafa Leonard Christopher Schmeel Ehrhardt Proksch Source Type: research

Successful treatment of recalcitrant generalized pustular psoriasis of pregnancy with spesolimab
J Dermatolog Treat. 2024 Dec;35(1):2334791. doi: 10.1080/09546634.2024.2334791. Epub 2024 Apr 2.ABSTRACTGeneralized pustular psoriasis (GPP) in pregnancy can lead to severe complications for both mother and fetus. The treatment of this disease is challenging, especially in recalcitrant and severe cases. Until present, there are no evidence-based guidelines for the treatment of GPP in pregnancy. Spesolimab, a human monoclonal antibody against the IL-36 receptor, has recently attracted attention as a new therapy for GPP flare. This biologic provides rapid and sustained control of symptoms of GPP flare, although its use in pr...
Source: Journal of Dermatological Treatment - April 2, 2024 Category: Dermatology Authors: Chenxin Yang Yang Wang Ruoyu Li Ping Tu Ruojun Wang Source Type: research

Use of a topical Janus kinase inhibitor in immune checkpoint inhibitor-induced eczematous reaction: a case report
In this report, we describe the case of a 28-year-old female with bilateral breast cancer in the setting of a BRCA1 mutation, who presented to dermatology with an eczematous reaction, ultimately diagnosed as a cutaneous immune-related adverse event (cirAE) secondary to an immune checkpoint inhibitor (ICI), pembrolizumab. Our case report highlights a novel therapeutic option for an eczematous cirAE: the topical JAK 1/2 inhibitor, ruxolitinib. CirAEs can occur in up to 55% of patients on ICIs, a class of medications seeing rapidly increasing use in cancer therapy, and prior research has demonstrated that ICI-induced dermatit...
Source: Journal of Dermatological Treatment - April 2, 2024 Category: Dermatology Authors: Camille M Powers Hannah Verma Jeremy Orloff Austin J Piontkowski Amy Tiersten Angela Lamb Nicholas Gulati Source Type: research

Short-term effectiveness and potential factors of ustekinumab based on real-world data in Chinese psoriasis patients
CONCLUSION: In this study, nearly one-third of patients achieved PASI 75 after only the first-dose ustekinumab treatment. Sex, family history of psoriasis, MS, serum TG level might affect the short-term effectiveness, and serum HDL-C level may be a potential factor. The possibility of achieving treatment goals (PASI 75/90/100) at week 4 increased along with serum HDL-C levels.PMID:38531383 | DOI:10.1080/09546634.2024.2321188 (Source: Journal of Dermatological Treatment)
Source: Journal of Dermatological Treatment - March 26, 2024 Category: Dermatology Authors: Xingyu Li Xiaowen Xie Jiashuai Li Jingjin Hu Kun Hu Minjia Tan Jing Yang Sichun Deng Yijie Liu Mi Zhang Yehong Kuang Junchen Chen Liqiu Liao Wu Zhu Source Type: research

A case of generalized eosinophilic pustular folliculitis: treatment with JAK inhibitor
CONCLUSIONS: JAK inhibitors show promise as a potential treatment option for EPF patients who do not respond to traditional therapies.PMID:38531388 | DOI:10.1080/09546634.2024.2331785 (Source: Journal of Dermatological Treatment)
Source: Journal of Dermatological Treatment - March 26, 2024 Category: Dermatology Authors: Chunzhi Zheng Yueqian Yu Guizhi Zhou Hong Liu Source Type: research

Short-term effectiveness and potential factors of ustekinumab based on real-world data in Chinese psoriasis patients
CONCLUSION: In this study, nearly one-third of patients achieved PASI 75 after only the first-dose ustekinumab treatment. Sex, family history of psoriasis, MS, serum TG level might affect the short-term effectiveness, and serum HDL-C level may be a potential factor. The possibility of achieving treatment goals (PASI 75/90/100) at week 4 increased along with serum HDL-C levels.PMID:38531383 | DOI:10.1080/09546634.2024.2321188 (Source: Journal of Dermatological Treatment)
Source: Journal of Dermatological Treatment - March 26, 2024 Category: Dermatology Authors: Xingyu Li Xiaowen Xie Jiashuai Li Jingjin Hu Kun Hu Minjia Tan Jing Yang Sichun Deng Yijie Liu Mi Zhang Yehong Kuang Junchen Chen Liqiu Liao Wu Zhu Source Type: research